At What Age Does Macular Degeneration Usually Start?

At What Age Does Macular Degeneration Usually Start?

Age-related macular degeneration most commonly begins after age 50, with risk rising steadily with each decade of life.(1–4) Early changes can appear in people in their 40s, but clinically significant AMD and most late-stage disease (geographic atrophy or neovascular AMD) occur in individuals aged 60 years and older.(2–5)

Key Facts at a Glance

• Age-related macular degeneration (AMD) is rare before age 50 and becomes progressively more common with advancing age.(1–4)
• In US data, early-stage AMD affects about 2% of adults aged 40–44, rising to ~12–20% of those ≥50 and >30% among people ≥85 years.(1,5,6)
• Late-stage, vision‑threatening AMD is extremely uncommon under age 60 and increases to around 5–11% among people aged 80–85 years or older.(2,5,6,7)
• A 45‑year‑old without early AMD has essentially 0% 3‑year risk of late AMD, whereas an 85‑year‑old with early AMD has an estimated 21% 3‑year risk of late disease.(2)
• Early‑onset AMD (diagnosed before age 50) exists but is rare; many cases in younger adults involve inherited macular dystrophies, not classic age-related AMD.(3,8)

How Age Influences the Development of AMD

Age-related macular degeneration results from cumulative damage to the retinal pigment epithelium (RPE), Bruch’s membrane, and choriocapillaris.(3,4,9) With aging, Bruch’s membrane thickens and accumulates lipids and proteins, reducing nutrient and waste exchange between the RPE and choroidal circulation.(3,4,9) Mitochondrial dysfunction and oxidative stress in RPE cells increase over time, and complement-mediated inflammation becomes more prominent.(3,4,9,10)

These age‑dependent changes promote the formation of drusen and basal deposits under the RPE, which are characteristic of early and intermediate AMD.(3,4,9) Because these processes accumulate gradually over decades, clinically apparent AMD typically emerges in later life. Genetic susceptibility (for example CFH or ARMS2/HTRA1 risk alleles) and environmental factors such as smoking and diet modulate how early these age‑driven mechanisms translate into visible macular pathology.(3,4,9–11)

Prevalence by Age Group

Large epidemiologic studies have quantified how AMD prevalence increases with age. A 2019 US modeling study estimated that among adults aged 50 years and older, early AMD prevalence ranged from 9.9–19.5%, and late AMD from 1.1–3.9%, depending on definitions and populations.(5,6)

CDC Vision and Eye Health Surveillance System (VEHSS) estimates show that early‑stage AMD prevalence rises from about 2% in people aged 40–44 to 46.6% in those aged 85 and older, although estimates at the oldest ages have wide uncertainty intervals.(1) Late-stage AMD prevalence increases from 0.02% among adults aged 40–44 to ~11% among adults aged ≥85 years.(6)

Prevent Blindness US summaries report that approximately 1 in 10 Americans aged 50 and older have early AMD, and about 1 in 100 in this age group have late, vision‑threatening AMD.(5) Among adults aged 80 and older, roughly 3 in 10 have early AMD and about 1 in 10 have late AMD.(5) These figures underscore that AMD is predominantly a disease of older adults, although early lesions can be found in middle‑aged individuals.

Risk of Developing AMD at Different Ages

The Three Continent AMD Consortium performed a pooled analysis of cohort data to estimate age‑specific 3‑year risks of developing or progressing AMD.(2) For a 65‑year‑old with no or early AMD, the 3‑year risk of late AMD was 0.5% or 7%, respectively; for an 85‑year‑old, comparable risks were 0.5% and 21%.(2) The 3‑year risk of developing early AMD itself was about 3% at age 65 and 12% at age 85.(2)

These findings show that early AMD can begin in the 60s or even late 50s, but the probability of progression to late disease grows much higher in the 70s and 80s. Age‑period‑cohort analyses from the Beaver Dam Eye Study also suggest that while age is the dominant factor, later‑born cohorts may have slightly lower incidence of early AMD, potentially due to lower smoking rates or better cardiovascular risk control.(7,12)

Early-Onset and “Younger” AMD

While most cases occur after age 50, AMD can occasionally be diagnosed in people in their 30s or 40s.(3,8,13) In younger adults, it is important to distinguish classic age-related AMD from inherited macular dystrophies (for example Stargardt disease, pattern dystrophies) and from myopic maculopathy, which may mimic AMD clinically but have different genetics and prognosis.(3,8,13)

When genuine AMD features—such as drusen, pigmentary changes, and typical fundus appearance—are seen in younger individuals, strong family history, high genetic risk, or environmental exposures (smoking, intense sunlight, poor diet) may play a larger role.(3,8,10,11) Nonetheless, early‑onset AMD remains rare, and most people will not encounter AMD until after mid‑life.

What Age Should People Start Eye Exams for AMD?

Guidelines from national eye institutes and professional societies generally recommend:

• A baseline comprehensive dilated exam by age 40–50 for adults without known eye disease, followed by periodic exams based on risk factors.(3,4,9)
• More frequent examinations for individuals over 55 years, particularly those with a family history of AMD, smoking history, or cardiovascular risk factors.(3,4,9–11)
• Immediate evaluation at any age if symptoms such as central blur, distortion, or a dark patch in vision occur.(3,4)

Because early AMD can be asymptomatic, regular dilated examinations in the 50s and 60s are essential to detect early lesions before significant vision loss occurs.

Summary

Age-related macular degeneration is primarily a disease of later life. Although early structural changes can appear in middle age, AMD most often becomes clinically evident after age 50, with prevalence and progression risk increasing steeply in the 60s, 70s, and 80s. Late-stage, vision‑threatening AMD is very rare under 60 and most common in people older than 75. Age interacts with genetic susceptibility and modifiable risk factors such as smoking and diet, so knowing your age‑related risk should prompt appropriate eye examinations and preventive measures rather than fatalism.

FAQs

Can someone in their 40s get age-related macular degeneration?
Yes, but it is uncommon. Early AMD changes can be detected in a small fraction of adults in their 40s, especially those with strong genetic or environmental risk factors, but late AMD is extremely rare at this age.(2,6,8,13)

Is AMD inevitable if I live long enough?
No. Although risk increases with age, many people in their 80s never develop advanced AMD.(2,5–7) Maintaining healthy behaviours and attending regular eye examinations can further reduce your chances of serious disease.

Does starting AMD at a younger age mean it will be more severe?
Not necessarily. Some younger individuals with early AMD remain stable for many years.(2,7,12) However, because they have more years ahead, ongoing monitoring and risk‑factor control are especially important.

At what age should I start getting checked for AMD if it runs in my family?
If you have a first‑degree relative with AMD, it is reasonable to have a baseline dilated exam in your 40s, with regular follow‑up from your 50s onward, or earlier if you notice visual symptoms.(3,4,9–11)

Is there a difference in age of onset between dry and wet AMD?
Neovascular (wet) AMD generally develops from pre‑existing dry AMD, so both forms typically appear in older adults.(2–4,6) Wet AMD is most often diagnosed in people aged 65 and older, although rare early‑onset cases occur.(2–4,6,8)

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. CDC Vision and Eye Health Surveillance System. Modeled estimates: age-related macular degeneration prevalence. 2024. Available from: https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html
2. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Incidence, progression and risk factors of age-related macular degeneration: Three Continent AMD Consortium report. Ophthalmology. 2022;129(5):571–582. Available from: https://bmjophth.bmj.com/content/7/1/e000912
3. Colijn JM, den Hollander AI, Cremers FPM, et al. Early and intermediate age-related macular degeneration: clinical characteristics and management. Clin Interv Aging. 2017;12:1347–1360. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5633280
4. NHS. Age-related macular degeneration (AMD). 2025. Available from: https://www.nhs.uk/conditions/age-related-macular-degeneration-amd
5. Rein DB, Flaxman AD, Andrews R, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1209–1217. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594
6. Prevent Blindness. Prevalence of age-related macular degeneration (AMD). 2025. Available from: https://preventblindness.org/amd-prevalence-vehss
7. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040. Lancet Glob Health. 2014;2(2):e106–e116. Available from: https://www.thelancet.com/journals/lango/article/PIIS2214-109X(13)70145-1/fulltext
8. WebMD. When AMD appears earlier in life. 2023. Available from: https://www.webmd.com/eye-health/macular-degeneration/amd-early-onset
9. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9834463
10. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134–143. Available from: https://academic.oup.com/hmg/article/26/R1/R45/3867129
11. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration. Ophthalmology. 2011;118(11):2203–2211. Available from: https://pubmed.ncbi.nlm.nih.gov/21762973
12. Klein R, Klein BE, Knudtson MD, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2003;110(4):682–690. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2577776
13. Healthline. Macular degeneration age of onset. 2023. Available from: https://www.healthline.com/health/eye-health/macular-degeneration-age-of-onset